Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Microneedling with 0.6 mm needles combined with 5% minoxidil is more effective for hair count and thickness than minoxidil alone or with 1.2 mm needles. Biweekly microneedling at 0.6 mm depth is recommended for better results in treating androgenetic alopecia.

A 25-year-old man with hair loss from bleach damage is using oral minoxidil and considering adding Dutasteride for better regrowth and prevention. He seeks advice on Dutasteride's effectiveness and potential benefits over finasteride, and is also curious about RU58841.

The conversation expresses frustration over the lack of clear evidence regarding the effectiveness and systemic impact of topical Dutasteride for hair loss treatment, despite years of discussion. People are criticized for not conducting proper research and for providing contradictory anecdotal claims.

People discussing hair loss treatments emphasize the need for patience, as results from using finasteride and minoxidil can take 8-12 months or longer. Some users report early signs of improvement, while others experience continued shedding or slower progress.

The conversation discusses microneedling for hair loss, with one user trying 0.3mm daily without feeling pain and questioning its effectiveness. Another user suggests that 0.3mm is too shallow and recommends 0.5mm twice a week or 0.75mm once a week for hair growth.

The conversation discusses whether age affects the side effects and effectiveness of hair loss treatments like finasteride and dutasteride. Some believe early treatment yields better results, while others mention varied outcomes across ages and personal regrowth experiences without a clear consensus on age impact.

A person started using finasteride, minoxidil, and dermarolling to regrow hair at the temples and is asking if it's possible. Some users report temple regrowth is possible with these treatments, while others find it challenging, and advise consistency and patience with treatment.

The conversation discusses the potential of long-chain unsaturated fatty acids, like oleic and linoleic acid, as an additional treatment for hair loss, which may inhibit the enzyme responsible for converting testosterone to DHT and promote hair growth. Users humorously suggest using oils topically and discuss other hair loss treatments, but the main focus is on the science behind fatty acids and their role in hair health.

Bryan Johnson uses a custom hair loss treatment that includes topical finasteride, minoxidil, azelaic acid, diclofenac, tea tree oil, rosemary oil, ginkgo biloba, biotin, and melatonin, which have shown varying degrees of effectiveness with minimal side effects. He also undergoes PRP and laser therapy, and has tried dutasteride mesotherapy.

The conversation discusses the effectiveness of hair loss treatments, specifically finasteride and dutasteride. The conclusion is that dutasteride significantly reduces DHT levels and may be more effective than finasteride for long-term hair retention, with some users reporting personal experiences and side effects.

The conversation discusses whether whey protein and creatine worsen hair loss. Some users report hair loss with creatine use, while others do not; opinions on whey protein's effects are mixed. Treatments mentioned include PRP, minoxidil, and finasteride.

The post discusses a user's experience with hair loss treatments, specifically topical finasteride, minoxidil, and micro-needling, and their plan to switch to oral versions and add Dutasteride. The conversation includes various responses, with some users sharing their own experiences and side effects, and others expressing desire for a more permanent hair loss solution.

The conversation is about the role of testosterone in hair loss and the effectiveness of different treatments. The conclusion is that DHT is the main culprit for hair loss, and finasteride has been proven to work long-term in maintaining and regrowing hair. Testosterone may have a minor effect, but it is not the primary cause of hair loss.

Microneedling for hair restoration involves daily use of a 0.3 mm device and weekly use of a 0.5 mm device. Combining microneedling with Minoxidil can enhance hair growth.

A user is experimenting with a hair loss treatment involving derma rolling and essential oils, avoiding expensive treatments and medications. They plan to shave their head, use a derma roller three times a week, apply Nizoral twice a week, and use a mix of Rosemary, Peppermint, and Jojoba Oil on non-rolling days.

Androgenetic alopecia is affected by scalp DHT levels, not sensitivity, with treatments like finasteride and dutasteride aiming to optimize these levels. Personalized DHT management is crucial for effective hair growth.

Young men are advised to delay hair transplants until after age 25, using finasteride, minoxidil, and dermarolling to manage hair loss. Concerns about unethical doctors highlight the need for careful planning.

Hmi115, a prolactin receptor blocker, showed promise for hair growth, but results from Phase 2 trials have not been published. ABS-201, an AI-based analog, is expected to begin trials in December 2025, while commercialization of treatments like PP-405 is anticipated around 2027.

GHK-RU58841 is used for hair loss, with positive results when combined with finasteride, stemoxydine, redensyl, and alfatradiol. Users report effectiveness after adding finasteride.

HopeMed is upset with Absci for allegedly using misleading information about HMI-115's performance compared to ABS-201. HopeMed plans to take legal action to protect its confidential data and trade secrets.

Kintor plans to release pyrilutamide foam and a plant-based Koshine by year-end, with GT20029 progressing in their pipeline. Users are pleased about the absence of propylene glycol (PG) in the new products.

KX826 shows promise as a hair loss treatment with a 10% increase in hair count, but concerns about Kintor's marketing practices and the systemic effects of treatments like GT20029 and RU58841 remain. Users express skepticism and hope, with some preferring traditional treatments like finasteride and minoxidil.

The conversation is about selling KY19382 powder, a novel activator of Wnt/β-catenin signaling, and Kolliphor EL liquid for vehicle formulation. The seller offers worldwide shipping.

The user experienced hair regrowth using Koshine KX-826 after two months, noticing new baby hairs and reduced shedding, while continuing to use Hims spray. They reported no side effects from Koshine and plan to keep monitoring progress.

OP developed hives after using Kx 826 (Pyrilutamide) 1% twice daily for 3 weeks. The hives appeared on the arms, chest, and groin area.

The user is concerned about hair loss despite taking finasteride and has a hair transplant scheduled. They experience scalp itching and burning, which hasn't been relieved by various treatments, and another user suggests using ghk-cu & ahk-cu serum and Koshine kx-826/pyrilutamide for relief.

Hope Medicine's HMI-115 is expected to be released in 2027, with phase 3 trials currently recruiting. Concerns include the safety of targeting prolactin and the potential cost of the treatment.

KY19382 is discussed as a potential treatment for creating new hair follicles and possibly curing hair loss. The conversation seeks user experiences and sourcing information for KY19382.

The post discusses the completion of the HMI-115 Australian Phase 1 Trial for hair loss treatment. The user speculates about the potential early release of the trial results.

Chime Biologics and Hope Medicine are speeding up the launch of a first-in-class antibody drug, HMI-115, for endometriosis and androgenic alopecia. The treatment involves a series of subcutaneous injections, has shown promising results in phase 1, and continues to promote hair regrowth even after the treatment is stopped.